JP2019534706A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534706A5
JP2019534706A5 JP2019520386A JP2019520386A JP2019534706A5 JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5 JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
seq
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520386A
Other languages
English (en)
Japanese (ja)
Other versions
JP7039577B2 (ja
JP2019534706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056093 external-priority patent/WO2018073680A1/en
Publication of JP2019534706A publication Critical patent/JP2019534706A/ja
Publication of JP2019534706A5 publication Critical patent/JP2019534706A5/ja
Priority to JP2021190070A priority Critical patent/JP7383682B2/ja
Application granted granted Critical
Publication of JP7039577B2 publication Critical patent/JP7039577B2/ja
Priority to JP2023191037A priority patent/JP2023184697A/ja
Priority to JP2025146227A priority patent/JP2025175010A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520386A 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート Active JP7039577B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021190070A JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
US62/409,081 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021190070A Division JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2019534706A JP2019534706A (ja) 2019-12-05
JP2019534706A5 true JP2019534706A5 (https=) 2020-11-12
JP7039577B2 JP7039577B2 (ja) 2022-03-22

Family

ID=60117722

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019520386A Active JP7039577B2 (ja) 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Country Status (22)

Country Link
US (5) US20190269791A1 (https=)
EP (3) EP4635516A3 (https=)
JP (4) JP7039577B2 (https=)
KR (1) KR102338660B1 (https=)
CN (2) CN110087691B (https=)
AU (3) AU2017344440B2 (https=)
CA (1) CA3040423A1 (https=)
DK (1) DK3525828T3 (https=)
ES (1) ES3007557T3 (https=)
FI (1) FI3525828T3 (https=)
HR (1) HRP20250056T1 (https=)
HU (1) HUE070615T2 (https=)
IL (2) IL310865A (https=)
LT (1) LT3525828T (https=)
MX (2) MX2019004434A (https=)
PL (1) PL3525828T3 (https=)
PT (1) PT3525828T (https=)
RS (1) RS66524B1 (https=)
RU (1) RU2758632C2 (https=)
SG (1) SG11201903400WA (https=)
SI (1) SI3525828T1 (https=)
WO (1) WO2018073680A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US12478686B2 (en) * 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
US20240252662A1 (en) * 2021-05-20 2024-08-01 Case Western Reserve University Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
CN121311252A (zh) * 2023-07-10 2026-01-09 上海药明合联生物技术有限公司 抗体药物偶联物及其生产
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU2001239470A1 (en) * 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
EP2174958A1 (en) 2002-03-11 2010-04-14 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature
BR0313043A (pt) * 2002-07-31 2005-06-14 Schering Ag Conjugados efetores, processo para sua produção e seu uso farmacêutico
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2607954A1 (en) * 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
JP5748392B2 (ja) 2005-10-05 2015-07-15 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 絹タンパク質
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
WO2008120101A2 (en) 2007-04-02 2008-10-09 Philogen S.P.A. The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
EP2167541B1 (en) 2007-07-25 2012-12-19 Philogen S.p.A. The ed-a antigen of fibronectin is associated with the neovasculature of tumour metastases
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
ES3000111T3 (en) * 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
GB2538023A (en) 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
PT3134127T (pt) * 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
TWI727380B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Similar Documents

Publication Publication Date Title
JP2019534706A5 (https=)
CN113423735B (zh) 抗-紧密连接蛋白抗体及其用途
US10517959B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
Richards Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery
JP2021502810A5 (https=)
JP2021532831A5 (https=)
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
Hassan et al. New life for immunotoxin cancer therapy
JP2018509908A5 (https=)
CN110869393A (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP2019531084A5 (https=)
Potala et al. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins
JP2017535246A5 (https=)
WO2012047724A4 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP7553633B2 (ja) Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP2016512832A5 (https=)
JP2016518332A5 (https=)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
JP2010535713A5 (https=)
FI3525828T3 (fi) Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja
Quiles et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
JP2020504607A5 (https=)
RU2018122629A (ru) Антитела против 5t4 и конъюгаты антитело-лекарственное средство